The Key Players in Global Kidney Cancer Drugs Market 2015-2019, According to a New Study on ASDReports

Monday 6 July 2015, Amsterdam

The report, now available on ASDReports, recognizes the following companies as the key players in the Global Kidney Cancer Drugs Market: Bayer, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis and Pfizer

Other Prominent Vendors in the market are: Abbott Laboratories, Active Biotech, Amgen, Argos Therapeutics, ArQule, AVEO Pharmaceuticals, Bionomics, Bristol-Myers Squibb, Cerulean Pharma, Exelixis, Genentech, immatics biotechnologies, Immunicum, Ono Pharmaceutical, Onyx Therapeutics, Oxford BioMedica, Prometheus Laboratories, Seattle Genetics, Taiwan Liposome, TRACON Pharmaceuticals and Wilex

Commenting on the report, an analyst from The report’s team said: “Individuals tend to develop resistance to monotherapies over a period, resulting in the increased preference for combination therapies, which are safe and more effective in the treatment of kidney cancer. For instance, Avastin (bevacizumab) in combination with interferons slows the proliferation of the disease. Combination drugs are selected depending upon the health condition of the patient and the severity of the disease. Combinations of IL-2 with interferons were more effective than IL-2 or interferon alone. Many other combination therapies are currently under investigation. For example, TRACON Pharmaceuticals is engaged in the phase II development of TRC-105 in combination with Inlyta for the treatment of RCC.”

According to the report, the prevalence of kidney cancer worldwide has increased in recent years. Changes in lifestyle, increased consumption of alcohol, excessive smoking, and a rise in obesity because of sedentary life routines lead to the growing incidence of the disease. Apart from these, the growing elderly population also results in a high incidence of the disease, as kidney cancer usually affects individuals aged 45 and above. In addition, the prevalence of the disease was higher in developed countries than in developing nations. These factors together account for a steady rise in the patient population opting for kidney cancer medication.

Further, the report states that a limited number of approved drugs for the treatment of kidney cancer are present in the market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.